General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Hepatocellular Carcinoma (HCC) in adults after prior therapy
Last updated January 29, 2019
Status:
Concluded without agreement
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Breast Cancer, Locally Advanced or Metastatic
Last updated January 29, 2019
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Metastatic Merkel Cell Carcinoma
Last updated January 17, 2019
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated January 15, 2019
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Acute Lymphoblastic Leukemia (ALL), Pediatric
Last updated January 15, 2019
Perjeta/Herceptin (pertuzumab/trastuzumab)
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Early Breast Cancer
Last updated December 28, 2018
Maviret (glecaprevir/pibrentasvir)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C
Last updated December 19, 2018
Status:
Concluded with an LOI
Manufacturer:
Valeant Canada
Indication:
Psoriasis, moderate to severe plaque
Last updated December 14, 2018
Status:
Concluded with an LOI
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Schizophrenia
Last updated December 14, 2018
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-Small Cell Lung Cancer (First Line)
Last updated December 11, 2018